Mounjaro just crossed a threshold no other GIP/GLP-1 medication has crossed before. The FDA has approved it specifically to reduce the risk of major cardiovascular events, heart attack, stroke, and cardiovascular death, in adults with type 2 diabetes who are at high risk for them.
This isn’t just a side benefit mentioned in fine print anymore. It’s now an official, FDA-recognized benefit on its own that we can add to the already established blood sugar control and weight-management benefits.
A Higher Bar Than Usual
The approval rests on SURPASS-CVOT, and the trial’s design is worth understanding because it set a higher bar than usual.
Most cardiovascular outcomes trials for diabetes drugs compare the medication against a placebo. This one didn’t. Instead, tirzepatide was tested head-to-head against dulaglutide (Trulicity), a GLP-1 medication with its own proven cardiovascular benefit, making it the first trial of its kind to compare two incretin therapies directly rather than against nothing.
Over 13,000 participants were enrolled across 30 countries and followed for a median of roughly four years, making it both the largest and longest tirzepatide trial completed to date.
What the Data Actually Shows
Taking a moment to understand what the data actually shows is worth it.
Tirzepatide demonstrated non-inferiority to dulaglutide. In other words, it worked at least as well, with an observed 8% lower rate of cardiovascular death, heart attack, or stroke. But the trial was explicitly designed to prove non-inferiority, not superiority, and the data didn’t establish superiority over dulaglutide.
Simply put, this trial shows tirzepatide protects the heart at least as well as an already-proven cardiovascular medication, not that it definitively beats it. That’s an exciting result, since dulaglutide’s proof of cardiovascular benefit was already hard-won against a placebo.
In other words, matching it is meaningfully different from simply controlling blood sugar. But it’s not the same claim as “tirzepatide is now proven superior for the heart,” and it’s worth being accurate about that.
Part of a Much Bigger Pattern
This approval fits into a much bigger pattern that’s been building for a while.
In just the last several months alone, research has piled up connecting GLP-1s to a lower risk of fractures despite greater weight loss, a real-world tirzepatide analysis showing a 32% lower risk of major cardiac events in high-risk diabetes patients, mounting evidence that these drugs may be working against inflammation itself rather than just weight, and cost data suggesting the medications may pay for a meaningful share of themselves in reduced hospitalizations and emergency visits over time.
None of these findings exists in isolation anymore. Together, they’re building a broader picture of GLP-1s doing a lot more than just appetite satiety.
But this FDA approval is the first time one of these threads has become an official, labeled indication rather than just an interesting data point in a research paper.
Why This Matters for GLP-1 Coverage
That distinction matters more than it might seem, especially for anyone who’s had to fight an insurance company for coverage. An FDA-approved cardiovascular indication is a different category of evidence in an insurer’s eyes than “research suggests.”
It’s reasonable to hope this is the first of several dominoes. Other trials investigating other conditions are already underway. Each one that clears the same bar makes it harder for insurers to wave away the case for broader coverage.
Real Progress, Fight Continues
Nothing about this changes the reality that access to these medications remains difficult for a lot of people right now, myself included. But approvals like this one are exactly the kind of evidence that eventually moves that needle.
A drug that started out narrowly defined as a diabetes and weight-loss medication just picked up a second, entirely distinct, FDA-recognized reason to be prescribed and covered. That’s real progress, even while the fight for broader access continues.
